Progress on Neoadjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer
10.3779/j.issn.1009-3419.2024.102.06
- VernacularTitle:可切除非小细胞肺癌新辅助免疫治疗研究进展
- Author:
QI CHANG
1
;
TIAN PANWEN
;
LI WEIMIN
Author Information
1. 610041 成都,四川大学华西医院呼吸与危重症医学科,呼吸和共病全国重点实验室,精准医学四川省重点实验室
- Keywords:
Lung neoplasms;
Neoadjuvant therapy;
Immune checkpoint inhibitors;
Perioperative period;
Resect-able non-small cell lung cancer
- From:
Chinese Journal of Lung Cancer
2024;27(2):138-146
- CountryChina
- Language:Chinese
-
Abstract:
In recent years,there has been a consensus regarding the enhancement of prognosis in patients with ad-vanced non-small cell lung cancer(NSCLC)through the utilization of immune checkpoint inhibitors(ICIs).Numerous clini-cal studies have also demonstrated the substantial value of immunotherapy for resectable NSCLC patients.Nevertheless,there remain controversies surrounding the exploration of immune combination strategies,treatment-related side effects,prognostic biomarkers,as well as other issues in the neoadjuvant therapy setting.Consequently,this article presents a comprehensive overview of the recent advancements in neoadjuvant immunotherapy for resectable NSCLC,stimulating fresh perspectives and delving into its merits and challenges in clinical application.
